Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 5;11:9587. doi: 10.1038/s41598-021-88983-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Platelet-induced cell invasion is reversed by resminostat in combination with sorafenib. (A) Effect of resminostat/sorafenib drug combination on platelet-induced cell invasion. PLC/PRF/5 cell invasion assay with 2.5 × 10⁷ PLTs/well (100 × 10³ PLTs/mm³) and without platelets. 1 µM resminostat and 2.5 µM sorafenib were used in mono- and combination treatments, 0.1% DMSO was used as the vehicle control. Representative microscopic images of transwells. (B) Quantification of cell invasion (right). The data are presented as mean ± SD (n = 3). One-way ANOVA with multiple comparison testing (Tukey) was performed. Multiplicity adjusted p-values with 95% confidence interval was applied. Adjusted p-values comparing vehicle control without vs. with platelets and compound treatments vs. vehicle control in the presence of platelets are presented in the figure. The stars indicate significant p-values, whereas ns indicates not significant. (C,D) Invasion assay with SNU-475 cells as described in (A) and (B). 2.5 µM resminostat and 5 µM sorafenib were used in mono- and combination treatments.